Literature DB >> 6090042

Antibody-dependent cell-mediated cytotoxicity to Varicella zoster.

J Babbage, A Sigfusson, R L Souhami.   

Abstract

Antibody-dependent cell-mediated cytotoxicity (ADCC) against Varicella zoster (VZ) infected fibroblasts is described. ADCC requires antibody to VZ and is greater with heavily infected targets. It is not dependent on the immune status of the effector cells. The effector cells responsible for ADCC are present in sheep red cell (E) positive and E-fractions of peripheral blood, and in the G10 non-adherent population. The ADCC activity is present in microexudate non-adherent cells and in the adherent population to a lesser extent. The technique provides a means to study host defence against VZ infection in immune compromised individuals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090042      PMCID: PMC1576969     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

2.  Specific in vitro antibody response to varicella zoster.

Authors:  R L Souhami; J Babbage; R E Callard
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

3.  Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody.

Authors:  C Ching; C Lopez
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

4.  Antibody-dependent cellular cytotoxicity to target cells infected with herpes simplex viruses: functional adequacy in the neonate.

Authors:  S L Shore; H Milgrom; P A Wood; A J Nahmias
Journal:  Pediatrics       Date:  1977-01       Impact factor: 7.124

5.  Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells.

Authors:  S Kohl; S E Starr; J M oleske; S L Shore; R B Ashman; A J Nahmias
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

6.  Cellular immunity to herpes simplex virus in man. VII. K-cell activity to HSV1 infected target cells in disease.

Authors:  A S Russell; G Essery
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

7.  The mononuclear cell in human blood which mediates antibody-dependent cellular cytotoxicity to virus-infected target cells. I. Identification of the population of effector cells.

Authors:  S L Shore; F M Melewicz; D S Gordon
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

8.  Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity.

Authors:  L K Borysiewicz; S Morris; J D Page; J G Sissons
Journal:  Eur J Immunol       Date:  1983-10       Impact factor: 5.532

9.  Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease.

Authors:  J C Ruckdeschel; S C Schimpff; A C Smyth; M R Mardiney
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

10.  Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease.

Authors:  J Cunningham; P Mauch; D S Rosenthal; G P Canellos
Journal:  Cancer Treat Rep       Date:  1982-04
View more
  3 in total

1.  Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes.

Authors:  O Pontesilli; P Carotenuto; M J Levin; D Suez; A R Hayward
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

2.  Interleukin 2 enhances natural killing of varicella-zoster virus-infected targets.

Authors:  M Ito; S Bandyopadhyay; M Matsumoto-Kobayashi; S C Clark; D Miller; S E Starr
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

3.  Human lymphocyte, monocyte and polymorphonuclear leucocyte mediated antibody-dependent cellular cytotoxicity against varicella-zoster virus-infected targets.

Authors:  T Ihara; M Ito; S E Starr
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.